Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28862433 | 0.98 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL10000247 | 0.98 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL17051572 | 0.98 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL17051575 | 0.93 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL10000254 | 0.90 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL17051530 | 0.88 | KDM1A (0.45) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL17051542 | 0.86 | CCR1 (0.56) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL17051585 | 0.84 | CCR1 (0.43) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL17051578 | 0.82 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL23084949 | 0.82 | MAPT (0.45) | NPC1RAB9ASMN1; SMN2LMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10038143-B2 | Polymer compound, material for electronic elements, material for organic electroluminescent elements, and organic electroluminescent element | IDEMITSU KOSAN CO., LTD. (JP) | 2018-07-31 | — | — | US | disclosed |
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-31 | — | — | US | disclosed |
| US-20150249215-A1 | POLYMER COMPOUND, MATERIAL FOR ELECTRONIC ELEMENTS, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, AND ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-03 | — | — | US | disclosed |
| US-8785445-B2 | 7-phenoxychroman carboxylic acid derivatives | ARRAY BIOPHARMA INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8158020-B2 | Liquid crystal element, optical path deflecting element, and image displaying apparatus | RICOH COMPANY, LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-8158020-B2 | Liquid crystal element, optical path deflecting element, and image displaying apparatus | RICOH COMPANY, LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080204608-A1 | Liquid Crystal Element, Optical Path Deflecting Element, and Image Displaying Apparatus | RICOH COMPANY, LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080204608-A1 | Liquid Crystal Element, Optical Path Deflecting Element, and Image Displaying Apparatus | RICOH COMPANY, LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | NPC1 36/4885RAB9A 3036/4885SMN1; SMN2 4162/4885 |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | NPC1 77/4885RAB9A 94/4885SMN1; SMN2 2668/4885 |
| US-20180148764-A1 | ENZYMATIC MODIFICATION OF NUCLEIC ACIDS | RNGTT, UNG, RNASEL | NPC1 2699/4885RAB9A 3130/4885SMN1; SMN2 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.